What is the share price of Vanta Bioscience Ltd (VANTABIO) today?

The share price of VANTABIO as on 10th September 2026 is ₹20.58. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

What is the return on Vanta Bioscience Ltd (VANTABIO) share?

The past returns of Vanta Bioscience Ltd (VANTABIO) share are Past 1 week: 5.00%Past 1 month: 5.00%Past 3 months: -17.45%Past 6 months: 6.08%Past 1 year: -14.78%Past 3 years: -50.71%Past 5 years: -84.76%

What are the peers or stocks similar to Vanta Bioscience Ltd (VANTABIO)?

The peers or stocks similar to Vanta Bioscience Ltd (VANTABIO) include: Vanta Bioscience Ltd Divi's Laboratories Ltd Syngene International Ltd Aarti Pharmalabs Ltd Vimta Labs Ltd Dishman Carbogen Amcis Ltd

What is the market cap of Vanta Bioscience Ltd (VANTABIO) share?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Vanta Bioscience Ltd (VANTABIO) is ₹14.64 Cr as of 10th September 2026.

What is the 52 week high and low of Vanta Bioscience Ltd (VANTABIO) share?

The 52-week high of Vanta Bioscience Ltd (VANTABIO) is ₹29 and the 52-week low is ₹14.71.

What is the PE and PB ratio of Vanta Bioscience Ltd (VANTABIO) stock?

The P/E (price-to-earnings) ratio of Vanta Bioscience Ltd (VANTABIO) is 146.36. The P/B (price-to-book) ratio is 3.87.

Which sector does Vanta Bioscience Ltd (VANTABIO) belong to?

Vanta Bioscience Ltd (VANTABIO) belongs to the Health Care sector & Labs & Life Sciences Services sub-sector.

How to buy Vanta Bioscience Ltd (VANTABIO) shares?

You can directly buy Vanta Bioscience Ltd (VANTABIO) shares on Tickertape. Simply sign up, connect your demat account and place your order.

Vanta Bioscience Ltd

VANTABIO Share Price

BSE

₹20.585.00% (+0.98)

Health Care

Labs & Life Sciences Services

Smallcap

With a market cap of ₹14 cr, stock is ranked 4,808

High Risk

Stock is 8.38x as volatile as Nifty

VANTABIO Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

Low

Profitability and efficiency haven't been upto the mark

Entry point

Bad

The stock is in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

Health Care

Labs & Life Sciences Services

Smallcap

With a market cap of ₹14 cr, stock is ranked 4,808

High Risk

Stock is 8.38x as volatile as Nifty

VANTABIO Performance & Key Metrics

No LabelNo Label	PB RatioPB Ratio	Dividend YieldDiv. Yield
—	3.87	—

Sector PESector PE	Sector PBSector PB	Sector Div YldSctr Div Yld
47.66	5.98	0.47%

VANTABIO Analyst Ratings & Forecast

—

Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

VANTABIO Company Profile

The company is a preclinical contract research company. It provides preclinical safety assessment services, assessment services for evaluating the safety of the active pharmaceutical ingredients (API), etc.

VANTABIO Similar Stocks (Peers)

Compare with peers Compare with peers

VANTABIO Similar Stocks (Peers)

Compare with peers Compare with peers

Divi's Laboratories Ltd

DIVISLAB

PE Ratio

97.28

1Y Return

54.46%

Buy Reco %

60.87

Syngene International Ltd

SYNGENE

PE Ratio

48.88

1Y Return

41.23%

Buy Reco %

62.50

Aarti Pharmalabs Ltd

AARTIPHARM

PE Ratio

43.94

1Y Return

5.95%

Buy Reco %

0.00

Vimta Labs Ltd

VIMTALABS

PE Ratio

35.53

1Y Return

19.39%

Buy Reco %

0.00

Dishman Carbogen Amcis Ltd

DCAL

PE Ratio

27.43

1Y Return

45.77%

Buy Reco %

0.00

Compare with Peers

VANTABIO Forecast

VANTABIO Forecasts

VANTABIO

Income

Balance Sheet

Cash Flow

Financial Year		FY 2018		FY 2019		FY 2020		FY 2021		FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	TTM
Total Revenue	4.04	12.65	14.25	10.07	10.11	6.97	9.83	2.07	1.98	0.00
Raw Materials	2.96	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.80	0.00
Power & Fuel Cost		0.98	1.04	0.54	0.55	0.75	1.01	0.43
Employee Cost		2.90	3.93	2.51	2.67	3.46	3.79	1.76
Selling & Administrative Expenses		3.23	3.30	1.94	2.00	3.08	2.53	2.26
Operating & Other expenses		2.04	1.50	1.10	1.00	1.38	1.08	1.77
EBITDA	1.08	3.50	4.48	3.98	3.89	-1.70	1.42	-4.15	1.18	0.00
Depreciation/Amortization	0.57	0.71	1.19	1.25	1.32	2.67	4.50	4.42	0.39	0.00
PBIT	0.51	2.79	3.29	2.73	2.57	-4.37	-3.08	-8.57	0.79	0.00
Interest & Other Items	0.20	1.69	1.95	2.14	2.35	5.89	5.75	4.07	0.78	0.00
PBT	0.31	1.10	1.34	0.59	0.22	-10.26	-8.83	-12.64	0.01	0.00
Taxes & Other Items	0.29	0.40	0.34	0.14	0.14	-3.78	-6.51	-7.86	-0.09	0.00
Net Income	0.02	0.70	1.00	0.45	0.08	-6.48	-2.32	-4.78	0.10	0.00
EPS	0.05	1.11	1.58	0.71	0.13	-10.27	-3.68	-7.57	0.15	0.00
DPS	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout ratio	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

VANTABIO Income Statement

Quarter		dec 2021		dec 2022	mar 2023
Total Revenue	0.00	2.83	1.29
Operating & Other expenses	0.00	3.37	1.93
EBITDA	0.00	-0.54	-0.64
Depreciation/Amortization	0.00	1.31	0.05
PBIT	0.00	-1.85	-0.69
Interest & Other Items	0.00	2.48	0.92
PBT	0.00	-4.33	-1.61
Taxes & Other Items	0.38	0.09	-0.01
Net Income	-0.38	-4.42	-1.60
EPS	0.00	-4.06	0.00

Financial Year		FY 2019		FY 2020		FY 2021		FY 2022	FY 2023	FY 2024	FY 2025
Cash from Operating Activities	-1.04	2.34	6.97	5.28	-0.63	2.68	-2.41
Cash from Investing Activities	-5.73	-7.59	-22.30	-17.24	-5.91	-3.31	-6.69
Cash from Financing Activities	9.94	2.17	17.78	9.53	6.41	0.69	9.16
Net Change in Cash	+3.17	-3.08	+2.45	-2.43	-0.13	+0.06	+0.06
Changes in Working Capital	-4.54	-2.14	+3.01	+1.39	+1.09	+1.32	+1.74
Capital Expenditures	2.48	0.35	0.86	0.33	28.69	3.40	6.69
Free Cash Flow	-3.52	1.99	6.11	4.95	-29.32	-0.72	-9.10

VANTABIO Company Updates

FY 2025FY 2025

Annual report

PDF

FY 2024FY 2024

Annual report

PDF

FY 2023FY 2023

Annual report

PDF

FY 2022FY 2022

Annual report

PDF

FY 2021FY 2021

Annual report

PDF

FY 2020FY 2020

Annual report

PDF

FY 2019FY 2019

Annual report

PDF

FY 2018FY 2018

Annual report

PDF

VANTABIO Stock Peers

VANTABIO Past Performance & Peer Comparison

Comparing 3 stocks from
Health CareLabs & Life Sciences Services

Valuation

Technical

Forecast

Compare valuation on Screener

Stock	PE RatioPE Ratio	PB RatioPB Ratio	Div. YieldDividend Yield
Vanta Bioscience Ltd	146.36	3.87	—
Divi's Laboratories Ltd	97.28	14.90	0.32%
Syngene International Ltd	48.88	3.20	0.33%
Aarti Pharmalabs Ltd	43.94	3.61	0.41%

Stock	Buy Reco %Buy Reco %	Upside %Upside %	1Y Fwd EPS Grwth1Y Forward EPS Growth
Vanta Bioscience Ltd	Pro
Divi's Laboratories Ltd
Syngene International Ltd
Aarti Pharmalabs Ltd

Stock	VolatilityVolatility	RSI–14DRSI – 14D	Price Mom RankPrice Momentum Rank
Vanta Bioscience Ltd	111.35%	96.08	Pro
Divi's Laboratories Ltd	24.48%	48.32
Syngene International Ltd	32.45%	36.43
Aarti Pharmalabs Ltd	44.38%	50.28

VANTABIO Stock Price Comparison

Compare VANTABIO with any stock or ETF

VANTABIO

VANTABIO Holdings

VANTABIO Shareholdings

VANTABIO Promoter Holdings Trend

VANTABIO Institutional Holdings Trend

No institutional holdings trend are available

VANTABIO Shareholding Pattern

VANTABIO Shareholding History

Foreign Institutions

VANTABIO Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing VANTABIO stock

Looks like this stock is not in any smallcase yet.

VANTABIO Events

VANTABIO Dividend Trend

Dividends

Corp. Actions

Announcements

Legal Orders

VANTABIO Dividend Trend

VANTABIO Dividends

Hmm, looks like data is unavailable here. Please come back after some time

VANTABIO Corp. Actions

Hmm, looks like data is unavailable here. Please come back after some time

No upcoming announcements are available

Others

Announced OnSep 5, 2026

Vanta Bioscience Ltd - 540729 - Board Me

Vanta Bioscience Ltd - 540729 - Board Me Download

Link

Download

Announced On

Sep 5, 2026

VANTABIO Legal Orders

Hmm, looks like data is unavailable here. Please come back after some time

VANTABIO Stock News & Opinions

Corporate

Vanta Bioscience’s board approved the 2025-26 Annual Report, scheduling a meeting for September 30, 2026

Vanta Bioscience Limited informed the BSE Limited that its board of directors approved the Annual Report for the financial year 2025-26 and fixed September 30, 2026, at 10:00 A.M. (IST) as the date, time, and venue for the 10th Annual General Meeting, with Mr. Zoheb S Sayani of Sayani & Associates appointed as the scrutinizer and Central Depository Services (India) Limited (CDSL) as the e-voting agency.

2 weeks agoCapital Market - Live

Corporate

Vanta Bioscience to discuss results

Vanta Bioscience will hold a meeting of the Board of Directors of the Company on 30 May 2026.

3 months agoCapital Market - Live

Corporate

Vanta Bioscience to discuss results

Vanta Bioscience will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live

10 months agoCapital Market - Live

Corporate

Vanta Bioscience to conduct AGM

Vanta Bioscience announced that the 9th Annual General Meeting(AGM) of the company will be held on 30 September 2025.Powered by Capital Market - Live